Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Adult Subjects With Stage 1 or Stage 2 Essential Hypertension.
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
At a glance
- Drugs PB 1046 (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- 18 Jun 2013 Top-line results reported in a PhaseBio Pharmaceuticals media release.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History